Galapagos NV (NASDAQ:GLPG – Get Rating) shares gapped up prior to trading on Monday . The stock had previously closed at $48.16, but opened at $50.65. Galapagos shares last traded at $51.65, with a volume of 1,778 shares trading hands.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Jefferies Financial Group cut shares of Galapagos from a "hold" rating to an "underperform" rating in a research report on Monday, July 25th. Morgan Stanley cut shares of Galapagos from an "overweight" rating to an "equal weight" rating and decreased their price objective for the company from $80.00 to $61.00 in a report on Friday, September 9th. Finally, Royal Bank of Canada decreased their price objective on shares of Galapagos from $62.00 to $55.00 in a report on Monday, August 8th. One analyst has rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $62.75.

Galapagos Stock Down 5.4 %

The stock's 50 day simple moving average is $52.54 and its two-hundred day simple moving average is $57.40.

Institutional Trading of Galapagos

A number of institutional investors have recently made changes to their positions in the business. International Biotechnology Trust PLC bought a new stake in shares of Galapagos in the second quarter worth $123,000. Driehaus Capital Management LLC lifted its position in shares of Galapagos by 6.9% in the second quarter. Driehaus Capital Management LLC now owns 510,649 shares of the biotechnology company's stock worth $28,494,000 after purchasing an additional 33,034 shares in the last quarter. Quantbot Technologies LP lifted its position in shares of Galapagos by 100.0% in the second quarter. Quantbot Technologies LP now owns 1,400 shares of the biotechnology company's stock worth $78,000 after purchasing an additional 700 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Galapagos by 193.8% in the second quarter. Renaissance Technologies LLC now owns 248,300 shares of the biotechnology company's stock worth $13,855,000 after purchasing an additional 163,800 shares in the last quarter. Finally, Hudson Bay Capital Management LP lifted its position in shares of Galapagos by 566.2% in the second quarter. Hudson Bay Capital Management LP now owns 216,500 shares of the biotechnology company's stock worth $12,081,000 after purchasing an additional 184,000 shares in the last quarter. Institutional investors own 19.48% of the company's stock.

About Galapagos

(Get Rating)

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis.

Featured Stories

• Get a free copy of the StockNews.com research report on Galapagos (GLPG)
• These 3 Reports Will Tell Us Much About the Current Economy
• Is Five Below Trying to Punch Too High?
• This Is What To Expect From The S&P 500 Now
• The Two Things You Need To Know About Oracle's FQ1 Report
• Three Value Stocks For A Volatile Market

Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.